Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 16,490

Document Document Title
WO/2020/097012A1
Disclosed are compounds of Formula (1), including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof, wherein A, Q, R1, R2, R3, R4, W and Y are as defined in the disclosure. Also disclosed are compositions containing...  
WO/2020/093715A1
In one aspect relates to the use of an amine compound in a process for the manufacture of a fluorinated or non-fluorinated 5-or 6-membered heterocyclic compound containing two nitrogen atoms in the ring system of the said compound, prefe...  
WO/2020/094440A1
The invention relates to a process for the synthesis of aryl hydrazinesof formula I or a salt thereof, which process comprises subjecting an arene of formula II to a coupling reaction with hydrazine or a derivative thereof, wherein the c...  
WO/2019/156946A3
Compositions and methods for improving CFTR function in cystic fibrosis affected cells with AR-13 and CFTR modulators are provided. In one aspect, methods of increasing the expression of CFTR in CF epithelial cells in a host by administe...  
WO/2020/087565A1
The present invention relates to a kinase inhibitor, comprising a compound represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention further relates to ph...  
WO/2020/092898A1
Disclosed are crystalline salts of Compound I, methods of preparing them, and related pharmaceutical preparations thereof. Also disclosed are methods of treatment using the crystalline salts of the invention.  
WO/2020/083377A1
The present invention relates to a class of pyrrolidinyl urea derivatives and an application thereof in the preparation of drugs for the treatment of diseases related to TrkA. Specifically disclosed are compounds represented by the formu...  
WO/2020/086728A1
In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured (Formula A) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.  
WO/2020/082605A1
The present invention relates to a pyrazolyl azophenol compound and the synthesis and derivation thereof. Specifically, the compound is 4-((1-methyl-1H-pyrazol-4-yl)diazenyl) phenol, and the structure thereof is as follows: formula I. Th...  
WO/2020/082921A1
Provided are a nitrogen heteroaryl amide derivative having the structure of formula (I), a preparation method therefor, and application thereof. Definitions of various substituents are as described in the specification and the claims. Th...  
WO/2020/083733A1
The present invention relates to the compounds of formula (I), and the N-oxides, stereoiso- mers, tautomers and agriculturally or veterinarily acceptable salts thereof wherein the variablesare defined according to the description, (I) Th...  
WO/2020/085504A1
A method for producing a compound represented by general formula (I) or a salt thereof by reacting a compound represented by general formula (II) or a salt thereof, with a diazotizing agent and hydrochloric acid, characterized by irradia...  
WO/2020/086533A1
The present disclosure provides, in part, 5-membered heteroaryl carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.  
WO/2020/084094A1
The present invention relates to a process for preparing a nitrated compound, comprising the step of reacting a compound (A) comprising at least one substituted or unsubstituted aromatic or heteroaromatic ring, wherein said heteroaromati...  
WO/2020/086732A1
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.  
WO/2020/085373A1
The present invention provides a novel compound which has activating activity selective for ERĪ². A compound represented by formula (1) or a salt thereof. (In the formula, R1 represents a cycloalkyl group having 3-8 carbon atoms, an alke...  
WO/2020/079207A1
The present invention relates to processes of preparing N- ((1,2,3,4,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopro pyl-1H- pyrazole-3-sulfonamide and salts thereof. The present invention further relates to pharmaceutical composition...  
WO/2020/079652A1
A DDR1 inhibitor compound can have a structure of Formula A, derivative thereof, prodrug thereof, salt thereof, stereoisomer thereof, tautomer thereof, polymorph thereof, or solvate thereof, or having any chirality at any chiral center, ...  
WO/2020/081381A1
Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein...  
WO/2020/081856A1
A compound of formula I, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: Formula I wherein X1 is benzimidazolyl, substituted benzimidazolyl, azabenzimidazolyl, substituted azabenzimidazolyl, pyrazolyl, or substi...  
WO/2020/080534A1
The present invention provides a method for controlling a plant disease by treating a plant or soil with a compound which has an excellent controlling effect on a plant disease and is represented by formula (I) [in the formula, Z represe...  
WO/2020/079111A1
Compounds of the formula (I), wherein the substituents are as defined in claim 1, useful as a pesticides, especially as fungicides.  
WO/2020/072797A1
Novel salts of niraparib are provided. Also provided are pharmaceutical compositions comprising those salts, as well as methods and uses pertaining to the same.  
WO/2020/063407A1
The present invention relates to general formulas (I) and (II) an N-aromatic amide compound and a preparation method therefor, a pharmaceutical composition and a pharmaceutical preparation containing the general formulas (I) and (II), an...  
WO/2020/065315A1
A composition comprising: a compound of formula (I): (I) wherein each of A, B, C and D are independently selected from: C1-18 alkyl; - CCl3; -CF3;C6-12 aryl optionally substituted with C1-18 alkoxy, -CN, -CF3, halogen, NO2, or C1-18 alky...  
WO/2020/069065A1
The present disclosure relates to chemical moieties which, when bonded to pharmacophores, cause the pharmacophores to undergo first pass metabolism. By undergoing first pass metabolism, a pharmacophore may be made less bioavailable. Such...  
WO/2020/065323A1
Provided is a process for preparing a compound, comprising the steps of a) Reacting a compound of Formula A (Formula A) with the compound 3 (3) to provide the compound 5 (5) or a salt or solvate thereof, wherein R is a linear or branched...  
WO/2020/060092A1
The present invention provides a novel prodrug of an edaravone compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising same as an active ingredient, and a use thereof in treatment or alleviation of...  
WO/2020/058945A1
The present invention is directed to methods of producing substituted pyrazole based compounds through novel intermediates and unique processes for preparing such intermediates which enables synthesis of final product through commerciall...  
WO/2020/056090A1
Disclosed are compounds of Formulae 1 and 10 including all geometric and stereoisomers, tautomers, N oxides, and salts thereof, wherein E, L, J, A, T, R1, R2a, R2b, X, Y, R6a, R6b and R29 are as defined in the disclosure. Also disclosed ...  
WO/2020/051344A1
This invention is directed to selective androgen receptor degrader (SARD) compounds including heterocyclic rings and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant...  
WO/2020/051402A1
Disclosed are compounds of Formula 1, including all geometric and stereoisomers, tautomers, N oxides, and salts thereof, wherein R1, R2, R3, R4, R5, R6, m and n are as defined in the disclosure. Also disclosed are compositions containing...  
WO/2020/048471A1
Disclosed are a 7-substituted indazole derivative as shown in formula (I) or a pharmaceutically acceptable salt thereof, and a preparation method therefor, and the use of the same as a therapeutic agent, especially as aIRAK4 kinase inhib...  
WO/2020/051260A1
This invention provides novel indole, indazole, benzimidazole, benzotriazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treatin...  
WO/2020/043998A1
The present invention relates to a method for the sigmatropic rearrangement of a compound of formula (I) wherein R3 and R4 are as defined in the description, which consists in thermally treating said compound by microwaves.  
WO/2020/046382A1
Disclosed are substituted heterocycle compounds including substituted pyrazoles, substituted pyrimidines, and substitute triazoles. The substituted heterocycles disclosed herein are shown to be useful in inhibiting c-MYC and may be utili...  
WO/2020/041905A1
Provided are uses of and methods of treatment involving a sulfonamide for treatment of central nervous system trauma, including but not limited to a spinal cord injury and/or a traumatic brain injury. The central nervous system trauma ma...  
WO/2020/040049A1
This composition includes a compound (A) represented by general formula (1) and a compound (B) represented by general formula (2), wherein the contained amount of the compound (B) is 0.00002-2.0 parts by mass with respect to 100 parts by...  
WO/2020/038279A1
A substituted pyrazole compound represented by formula I, and a preparation method, a pharmaceutical composition, and use thereof. The compound has good stability, excellent solubility, small cell toxicity, and a significant effect on ne...  
WO/2020/041562A1
This disclosure relates to low molecular weight substituted imidazoles that inhibit the TGF-b signaling pathway. More specifically, this disclosure relates to methods of using said imidazoles for the treatment of diseases related to the ...  
WO/2020/039456A1
The present invention provides a novel 1:1 co-crystal of (rac)-tramadol hydrobromide-celecoxib and processes for the preparation of the same by reacting (rac)-tramadol with hydrobromic acid and celecoxib. It also provides crystalline for...  
WO/2020/040048A1
This composition includes a compound (A) represented by general formula (1) and a compound (B) represented by general formula (2), wherein the contained amount of the compound (B) is 0.00002-0.2 parts by mass with respect to 100 parts by...  
WO/2020/040050A1
Provided are: a composition that has excellent stability during storage and excellent stability during use; and a production method for the composition. The composition according to the present invention includes a compound (A) represent...  
WO/2020/040045A1
Provided are: a composition that has excellent stability during storage and excellent stability during use; and a production method for the composition. This composition includes a compound (A) represented by general formula (1), and a c...  
WO/2020/041100A1
Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein...  
WO/2020/035464A1
The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 and R3 are each independently hydrogen or an optionally substituted hydrocarbyl group, or R1 and R3 together with the nitrogen atom to which...  
WO/2020/035540A1
Heteroaromatic carboxamides of formula (I), wherein Y, R, and X are as defined in the description and the claims, and pharmaceutically acceptable salts thereof can be used in methods for the treatment of diseases which can be influenced ...  
WO/2020/025449A1
Object of the present invention is a highly stable crystalline form of Eltrombopag (ETP) monoethanolamine salt, named Form D1, having the highest thermodynamically stability with excellent non-hygroscopicity, and particularly well suitab...  
WO/2020/027225A1
One of the purposes of the present invention is to provide a heterocyclic derivative that has an IAP (particularly XIAP) binding (inhibiting) activity. Another of the purposes of the present invention is to provide a heterocyclic derivat...  
WO/2020/027214A1
A method is provided which, by applying a compound represented by formula (1) or an N-oxide or agriculturally acceptable salt thereof, controls soybean rust fungus having an amino acid substitution of F129L in the mitochondrial cytochrom...  

Matches 1 - 50 out of 16,490